#31: KAL News General Research Equity Analyst Initiates Coverage of Callisto with Projected 6-Month Share Price Target of $2.20; German-Based Analyst Praises Callisto's Anti-Cancer and Other Drug Development Programs, Recommends a Buy Rating
NEW YORK--(BUSINESS WIRE)--Dec. 28, 2005--Callisto Pharmaceuticals, Inc. (AMEX:KAL) (FWB:CA4), a developer of new drug treatments in the fight against cancer and other major health threats, today...
#30: KAL News Callisto Establishes Guanilib as Developmental Name for Novel Drug Candidate for GI Disease; Name Established as Company Moves Forward with First-in-Class Compound Planned for Clinical Trial
NEW YORK--(BUSINESS WIRE)--Dec. 22, 2005--Callisto Pharmaceuticals, Inc. (AMEX:KAL) (FWB:CA4), a developer of new drug treatments in the fight against cancer and other major health threats, has...
#28: KAL News Callisto Pharmaceuticals Reports on 2005 Clinical and Corporate Milestones and Achievements; Company Cites Progress in Anti-Cancer Drug Development and Development and Expansion of Intellectual Property
NEW YORK--(BUSINESS WIRE)--Dec. 19, 2005--Callisto Pharmaceuticals, Inc. (AMEX:KAL)(FWB:CA4), a developer of new drug treatments in the fight against cancer and other major health threats, has...
NEW YORK--(BUSINESS WIRE)-19. Dez. 2005--Callisto Pharmaceuticals, Inc. (AMEX:KAL)(FWB:CA4), ein Entwickler neuer Arzneimittelbehandlungen im Kampf gegen Krebs und andere Gesundheitsrisiken,...
#27: KAL News Callisto's Program to Develop Biowarfare Vaccines Featured in Audio Interview with HomelandInsights.com; CEO Discusses Callisto Homeland Security Program to Fight Threat of Dangerous Superantigen Bacterial Weapons
LOS ANGELES--(BUSINESS WIRE)--Dec. 16, 2005--HomelandInsights.com, http://www.homelandinsights.com, the online source for exclusive investor information in the homeland security and defense market,...
#26: KAL News Callisto Discusses Drug Candidate for Gastro-Intestinal Disease in Audio Interview with BiomedDiscoveries.com; Drug Candidate Being Developed as Treatment for Gastro-Intestinal Diseases
LOS ANGELES--(BUSINESS WIRE)--Dec. 15, 2005--BiomedDiscoveries.com, http://www.BiomedDiscoveries.com, the online source for exclusive investor information in the biotechnology sector, announced...
#25: KAL News Callisto Cites New Research Data on Cancer Drug Atiprimod in Presentations at American Society of Hematology Meeting; Company Announces Plan for Next Phase of Trial Following Release of Additional Clinical and Pre-Clinical Data
NEW YORK--(BUSINESS WIRE)--Dec. 14, 2005--Callisto Pharmaceuticals, Inc. (AMEX:KAL) (FWB:CA4), a developer of new drug technologies in the fight against cancer and other serious healthcare threats,...
#24: KAL News Callisto Pharmaceuticals Outlines Latest Major Achievements and Clinical Progress in Investor Conference Call; Company Officers Also Discuss Plans for Next Clinical Investigations into Anti-Cancer Drug Candidates
NEW YORK--(BUSINESS WIRE)--Dec. 14, 2005--Callisto Pharmaceuticals, Inc. (AMEX:KAL) (FWB:CA4), a developer of new drug treatments in the fight against cancer and other major health threats,...
#23: KAL News Callisto Research Note Issued by Beacon Equity Research, Reiterates Share Price Growth Target of $3.10; Investrend Research Affiliate Cites Recent Milestone Launch of Adult Clinical Trials of L-Annamycin Drug Candidate
NEW YORK--(BUSINESS WIRE)--Dec. 12, 2005--A new research note on Callisto Pharmaceuticals Inc. (AMEX:KAL) has been issued by Beacon Equity Research Senior Analyst, Shailesh Dhuri. The fee-based...
#22: KAL News Web Alert: Callisto to Host Investor Conference Call Today to Discuss Developments in Anti-Cancer Drug Trials and IP Growth; Senior Management to Provide Progress Report on Recent Achievements During Call Scheduled to Start 12 p.m. Eastern
NEW YORK--(BUSINESS WIRE)--Dec. 12, 2005--Callisto Pharmaceuticals, Inc. (AMEX:KAL) (FWB:CA4), a developer of new drug treatments in the fight against cancer and other major health threats, will...
#21: KAL News Callisto's Initiative to Expand IP Business Development Potential Featured in New Online Interview on SmallCapInsights.com; CEO Dr. Gary S. Jacob Discusses New Division's Goals to Expand IP Portfolio and Extend-Licensing Opportunities
LOS ANGELES--(BUSINESS WIRE)--Dec. 9, 2005--SmallCapInsights.com, the online source for exclusive commentary, research, interviews and other information about the Smallcap investment marketplace,...
#20: KAL News Callisto Corporate Video Presentation Focuses on Company's Anti-Cancer Drug Candidates as Second Clinical Trial Starts; Video Presentation Spotlights Company's Drug Candidates to Treat Relapsed Leukemia and Multiple Myeloma Cancers
NEW YORK--(BUSINESS WIRE)--Dec. 9, 2005--Callisto Pharmaceuticals, Inc. (AMEX:KAL) (FWB:CA4), a developer of new drug treatments in the fight against cancer and other major health threats, has...
NEW YORK--(BUSINESS WIRE)--Dec. 9, 2005--Callisto Pharmaceuticals, Inc. (AMEX:KAL)(FWB:CA4), a developer of new drug treatments in the fight against cancer and other major health threats, today...
#18: KAL News Callisto Establishes Intellectual Property Department to Expand New Drug Pipeline and Strengthen Patent Protection; Veteran Biotechnology Executive and Patent Agent David Ladner Named Director of New Department
NEW YORK--(BUSINESS WIRE)--Dec. 8, 2005--Callisto Pharmaceuticals, Inc. (AMEX:KAL)(FWB:CA4), a developer of new drug treatments in the fight against cancer and other major health threats, today...
#17: KAL News Callisto Outlines Achievements in Development of Anti-Cancer Drug Candidates and Other Recent Advances in Online Interview; CEO Dr. Gary Jacob Discusses Latest Clinical Milestones and Strategic Initiatives with Wall Street Reporter
NEW YORK--(BUSINESS WIRE)--Dec. 8, 2005--Callisto Pharmaceuticals, Inc. (AMEX:KAL)(FWB:CA4), a developer of new drug treatments in the fight against cancer and other major health threats, today...
